Clinical Trial: The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL

U.S., April 8 -- ClinicalTrials.gov registry received information related to the study (NCT07514169) titled 'The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL' on March 29.

Brief Summary: This is a prospective, single-center, open-label, single-arm clinical study designed to evaluate the efficacy and safety of Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen in older treatment-naive patients with large B-cell lymphoma.

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Large B-Cell Lymphoma (LBCL)

Intervention: DRUG: Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Lenalidomide and Glofitamab) regimen

Pola-ZR-Glo (Polatuzumab Vedotin, Zanubrutinib, Len...